We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Ticker | Name | Price | Change | Change % | Volume | Trades |
---|---|---|---|---|---|---|
CNJ | Conico Ltd | 0.002 | 0.001 | 100.00% | 6,822,014 | 15 |
RNE | Renu Energy Limited | 0.002 | 0.001 | 100.00% | 1,529,161 | 7 |
ICU | Investor Centre Ltd | 0.006 | 0.003 | 100.00% | 463,332 | 7 |
TMSO | Tennant Minerals Ltd | 0.002 | 0.001 | 100.00% | 2,900,000 | 7 |
INP | IncentiaPay Limited | 0.005 | 0.002 | 66.67% | 391,140 | 6 |
AZ9 | Asian Battery Metals PLC | 0.033 | 0.012 | 57.14% | 2,359,556 | 16 |
M2ROA | Miramar Resources Limited | 0.003 | 0.001 | 50.00% | 27,496,128 | 31 |
M2R | Miramar Resources Limited | 0.01 | 0.003 | 42.86% | 10,584,617 | 73 |
BIM | Bindi Metals Ltd | 0.105 | 0.027 | 34.62% | 1,605,550 | 58 |
OAR | OAR Resources Limited | 0.002 | 0.0005 | 33.33% | 293,956 | 4 |
EDE | Eden Innovations Ltd | 0.002 | 0.0005 | 33.33% | 2,562,842 | 7 |
Exicure, Inc. (“Exicure” or the “Company”) (Nasdaq: XCUR), announced today that on September 17, 2024, the Company received notice that the Nasdaq Hearings Panel (“Panel”) granted an extension to continue the Company’s listing subject to the Company evidencing compliance with all applicable criteria for continued listing on The Nasdaq Capital Market by November 14, 2024. The Company is diligently working to timely satisfy the terms of the Panel’s requests and to ensure the Company’s continued listing on Nasdaq.
Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced top-line data of EDG-7500 from the Phase 1 trial in healthy subjects and the single-dose arm of the Phase 2 CIRRUS-HCM trial in patients with obstructive HCM. EDG-7500 is a novel oral, selective, cardiac sarcomere modulator, specifically designed to slow early contraction velocity and address impaired cardiac relaxation associated with HCM.
The planned expansion consists of two additional programs over the next two years. One program aims to identify novel Aramchol-based drug combinations to overcome resistance to standard-of-care oncological treatments for patients with advanced colorectal and hepatic cancers. Another program aims to unravel new mechanisms of action that will allow the development of a novel Aramchol-based drug combination targeting cardiac fibrosis, or scarring of the heart, which occurs in many cardiovascular diseases that can lead to heart dysfunction and failure. The Company plans on releasing new data from in-vitro and ex-vivo studies in these programs during the fourth quarter of 2024.
Shipments will support the Space Development Agency's Tranche 1 program MUNICH, Sept. 16, 2024 /PRNewswire/ -- Mynaric (NASDAQ: MYNA) (FRA: M0YN), a leading provider of industrialized, cost-effective and scalable laser communications products, today announced the successful advancement of the company's volume production ramp for the CONDOR Mk3. Mynaric continues to work through previously announced production delays and has realized near-term improvement in production yields and supply chain-related bottlenecks. Production delays of CONDOR Mk3 were caused by lower than expected production yields and supplier shortages of key components.
Ticker | Name | Price | Change | Change % | Market Cap | Volume |
---|---|---|---|---|---|---|
BTC | Bitcoin | 63,319.07 | 1,645.31 | 2.67% | 1.24T | 6,324,027,359 |
ETH | Ethereum | 2,458.71 | 88.80 | 3.75% | 295.8B | 2,219,451,949 |
USDT | Tether USD | 1.00 | 0.00 | 0.00% | 97.84B | 314,373,752 |
BNB | Binance Coin | 568.88 | 9.33 | 1.67% | 90.17B | 248,044,086 |
SOL | Solana | 142.69 | 8.45 | 6.29% | 63.05B | 1,261,439,961 |
XRP | Ripple | 0.5904 | 0.0051 | 0.87% | 32.13B | 266,548,677 |
USDC | USD Coin | 0.99992 | 0.00002 | 0.00% | 28.07B | 1,104,326,022 |
STETH | stETH | 2,457.86 | 89.88 | 3.80% | 24.14B | 5,215,010 |
TONCOIN | Wrapped TON Coin | 5.72 | 0.067761 | 1.20% | 19.86B | 97,247,157 |
DOGE | Dogecoin | 0.10557 | 0.00189 | 1.82% | 15.14B | 190,569,683 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions